[go: up one dir, main page]

EA200701166A1 - Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин - Google Patents

Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин

Info

Publication number
EA200701166A1
EA200701166A1 EA200701166A EA200701166A EA200701166A1 EA 200701166 A1 EA200701166 A1 EA 200701166A1 EA 200701166 A EA200701166 A EA 200701166A EA 200701166 A EA200701166 A EA 200701166A EA 200701166 A1 EA200701166 A1 EA 200701166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
timozyny
antjovants
peptides
cancer vaccines
Prior art date
Application number
EA200701166A
Other languages
English (en)
Other versions
EA015510B1 (ru
Inventor
Густаво Антонио Мовиглия
Алфред Р. Рудолф
Original Assignee
Сциклон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сциклон Фармасьютикалс, Инк. filed Critical Сциклон Фармасьютикалс, Инк.
Publication of EA200701166A1 publication Critical patent/EA200701166A1/ru
Publication of EA015510B1 publication Critical patent/EA015510B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В заявке описаны фармацевтическая комбинация и способ повышения эффективности противораковой вакцины у субъекта, применение индуцирующей иммунный ответ противораковой вакцины, способной вызывать ответ иммунной системы у субъекта, и количество альфа-тимозинового пептида, повышающего эффективность вакцины, повышающее ответ иммунной системы у субъекта, причем противораковая вакцина и альфа-тимозиновый пептид могут вводиться в организм по отдельности или совместно.
EA200701166A 2004-12-06 2005-12-06 Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация EA015510B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (2)

Publication Number Publication Date
EA200701166A1 true EA200701166A1 (ru) 2008-02-28
EA015510B1 EA015510B1 (ru) 2011-08-30

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701166A EA015510B1 (ru) 2004-12-06 2005-12-06 Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация

Country Status (15)

Country Link
US (1) US20100092499A1 (ru)
EP (1) EP1835931A4 (ru)
JP (1) JP2008523067A (ru)
KR (1) KR20070086663A (ru)
CN (1) CN101072582B (ru)
AU (1) AU2005314271B2 (ru)
BR (1) BRPI0518571A2 (ru)
CA (1) CA2588685A1 (ru)
EA (1) EA015510B1 (ru)
IL (1) IL183264A (ru)
MX (1) MX2007006717A (ru)
NO (1) NO20072705L (ru)
NZ (1) NZ555571A (ru)
UA (1) UA90493C2 (ru)
WO (1) WO2006062917A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
AU2013210783B2 (en) * 2012-01-20 2017-12-07 Cellvax Therapeutics Inc. Autologous cancer cell vaccine
KR20150035495A (ko) * 2012-03-08 2015-04-06 사이클론 파아머슈티컬 인코오퍼레이티드 화농성 비부비동염 치료를 위한 티모신 알파의 용도
US9724395B2 (en) * 2014-10-21 2017-08-08 Sciclone Pharmaceuticals, Inc. Treatment of cancer with immune stimulators
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
JP2004500029A (ja) * 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
NZ532863A (en) * 2001-10-26 2006-07-28 Rhode Island Hospital Thymosin augmentation of genetic immunization for the treatment of hepatitis C
CA2490868A1 (en) * 2002-06-28 2004-01-08 Sciclone Pharmaceuticals Inc. Method of up-regulating tumor antigen expression using thymalfasin
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Also Published As

Publication number Publication date
JP2008523067A (ja) 2008-07-03
AU2005314271A1 (en) 2006-06-15
CN101072582B (zh) 2012-06-27
IL183264A (en) 2010-12-30
EP1835931A4 (en) 2008-12-17
AU2005314271B2 (en) 2011-06-16
UA90493C2 (ru) 2010-05-11
KR20070086663A (ko) 2007-08-27
WO2006062917A3 (en) 2006-11-16
CA2588685A1 (en) 2006-06-15
CN101072582A (zh) 2007-11-14
NZ555571A (en) 2009-02-28
EA015510B1 (ru) 2011-08-30
WO2006062917A2 (en) 2006-06-15
BRPI0518571A2 (pt) 2008-11-25
EP1835931A2 (en) 2007-09-26
IL183264A0 (en) 2007-09-20
US20100092499A1 (en) 2010-04-15
MX2007006717A (es) 2007-08-06
NO20072705L (no) 2007-09-05

Similar Documents

Publication Publication Date Title
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
ES2485316T3 (es) Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2010066418A8 (de) Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung
WO2007103048A3 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2006115843A3 (en) Nipah virus vaccines
WO2008054535A3 (en) Novel influenza m2 vaccines
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
EP4226938A3 (en) Coronavirus vaccine
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MD20100029A (ro) Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) si vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
EA200602137A1 (ru) Гидрогелевые препараты интерферона
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
WO2005007673A3 (en) Immunogenic peptides
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
EA200702079A1 (ru) Вакцина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU